Europe Allogeneic Human Chondrocyte Market Driven By High Prevalence of Musculoskeletal Injuries in Europe
Allogeneic human
chondrocyte is an emerging therapy that can be used for cartilage repair and
other indications. It finds application in the treatment of musculoskeletal
disorders and cartilage defects. It helps to reduce the risk of host-immune
rejection due to its autologous nature and facilitates direct restoration of
hyaline cartilage. Moreover, the therapy is less invasive and offers shorter
recovery times compared to alternative, comparable therapies.
The Europe allogeneic human chondrocyte
market is expected to witness significant growth, owing to
high prevalence of musculoskeletal injuries in the region. According to the
Study, ‘Prevalence of Musculoskeletal Injuries, Pain, and Illnesses in Elite
Female Basketball Players, in Europe, in June 2019, the most frequently injured
body parts were lower limbs: more than 60%, representing an injury rate of 0.14
per athletes and a 0.2 pain rate per athlete (during the study period).
Allogeneic human
chondrocyte can be used in the treatment of osteoarthritis. According to the
study ‘Osteoarthritis in Europe: Impact on health status, work productivity and
use of pharmacotherapies in five European countries’ that examined the impact
of peripheral joint osteoarthritis across five European countries, the U.K.
(43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%)
recorded high prevalence of peripheral joint osteoarthritis, with majority of
cases aging 55-74 years. Such scenario suggests that high prevalence of osteoarthritis
is expected to boost growth of the Europe allogeneic human chondrocyte market.
The Europe allogeneic
human chondrocyte market is also driven by partnership strategies among market
players. For instance, in January 2020, Mundipharma Deutschland GmbH & Co.
KG, a pharmaceutical company, signed sales agreement with Biosolution Co., Ltd,
a Korea-based company focused on R&D in cell-based biotechnology, to market
and distribute its fourth-generation autologous chondrocyte implantation
product, CartiLife.
Comments
Post a Comment